HeartFlow, Inc.

HeartFlow, Inc. is a medical technology company that applies artificial intelligence to the management of coronary artery disease (CAD). Its software analyses standard coronary CT angiography (CCTA) images to build detailed 3D models of the heart, supporting clinicians in diagnosing, treating and managing CAD without invasive procedures. The company is headquartered in San Francisco, California, and operates in the United States, Europe and Japan. It is publicly traded on Nasdaq under the ticker HTFL.

The company's technology spans several engineering domains: artificial intelligence, medical imaging, 3D modelling of the heart, computational fluid dynamics and blood flow simulation, and plaque quantification. Its flagship platform, HeartFlow One, is described as a complete, non-invasive precision coronary care platform covering the guideline-directed CCTA pathway. Its component analyses include Roadmap Analysis, which visualises and quantifies coronary narrowings; FFRCT Analysis, which uses personalised 3D simulations to assess the effect of blockages on blood flow; and Plaque Analysis, which characterises and quantifies coronary atherosclerosis.

HeartFlow reports that its solutions have been used for more than 600,000 patients and adopted by over 1,800 institutions. The technology is supported by more than 625 peer-reviewed publications and is referenced in ACC/AHA guidelines. In the United States, its payer coverage extends to 99.5% of lives through Medicare and major commercial insurers.

The company states a mission to transform CAD from the leading cause of death into a disease that can be managed for life, and describes its approach as evidence-based and innovation-led.